Specific IgA antibody to Epstein-Barr viral capsid antigen: A better marker for screening nasopharyngeal carcinoma than EBV-DNA detection by polymerase chain reaction
W. Kantakamalakul et al., Specific IgA antibody to Epstein-Barr viral capsid antigen: A better marker for screening nasopharyngeal carcinoma than EBV-DNA detection by polymerase chain reaction, A P J ALLER, 18(4), 2000, pp. 221-226
Nasopharyngeal carcinoma (NPC) is strongly associated with Epstein-Barr vir
us (EBV) infection. To assess whether EBV DNA detection by polymerase chain
reaction (PCR) or presence of specific serum antibody to viral capsid anti
gen (VCA) was a better marker for screening NPC, nasopharyngeal tissues and
blood samples from 58 NPC patients and 24 non-NPC patients (23 with laryng
otracheal stenosis and 1 with chronic tonsillitis) were tested for the pres
ence of EBV DNA and serum specific VCA antibodies, respectively. EBV DNA wa
s detected in 56 (96.5%) of NPC patients and 15 (62.5%) of non-NPC controls
, with predominantly EBV type A in both groups. On the other hand, specific
VCA IgA antibody was detected in the majority of NPC patients: 52 (89.7%)
while only 4 (16.7%) were detected in non-NPC controls. Therefore, specific
VCA IgA antibody may serve as a better marker for screening NPC than EBV D
NA detected by PCR.